Review
Oncology
Hoda Mahdavi
Summary: Locally advanced stages of squamous cancers of the head and neck (LAHNCs) have a high risk of local and systemic relapse. The addition of induction therapy to the standard concurrent chemoradiotherapy (CCRT) has been widely used but did not improve survival rates in unselected populations. The TPF induction regimen showed superiority but did not demonstrate a survival advantage over CCRT alone. Newer systemic therapy combinations are currently being tested to find more effective treatments for LAHNCs.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Article
Oncology
Szu-Han Hu, Ming-Yii Huang, Chung-Yu Chen, Hui-Min Hsieh
Summary: This study examines the treatment trends and survival effects of locally advanced head and neck cancer patients in Taiwan before and after the coverage of cetuximab by the National Health Insurance. The study found an increasing trend in the utilization of cetuximab among these patients, but overall usage rates were low. Additionally, patients receiving cetuximab with other treatments had higher mortality risk compared to those receiving cisplatin.
Article
Oncology
Thana Patimarattananan, Arkom Nongnuch, Poompis Pattaranutaporn, Nattawut Unwanatham, Chuleeporn Jiarpinitnun, Nuttapong Ngamphaiboon
Summary: An incidence of 34% cisplatin-induced acute kidney injury was reported in locally advanced head and neck squamous cell carcinoma patients. One third of patients who underwent cisplatin-based chemoradiotherapy developed acute kidney disease (AKD), with eGFR not recovering to baseline even after 1 year. Factors associated with AKD included ECOG status 0 and hypertension.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Oncology
L. Belgioia, C. Becherini, A. Bacigalupo, P. Bonomo
Summary: Immunotherapy plays a significant role in the treatment of head and neck squamous cell carcinoma, but its role in upfront management of locally advanced disease and its integration with standard of care remains unclear.
Article
Oncology
Nancy Y. Lee, Robert L. Ferris, Amanda Psyrri, Robert Haddad, Makoto Tahara, Jean Bourhis, Kevin Harrington, Peter Mu-Hsin Chang, Jin-Ching Lin, Mohammad Abdul Razaq, Maria Margarida Teixeira, Jozsef Lovey, Jerome Chamois, Antonio Rueda, Chaosu Hu, Lara A. Dunn, Mikhail Vladimirovich Dvorkin, Steven De Beukelaer, Dmitri Pavlov, Holger Thurm, Ezra Cohen
Summary: This study aimed to evaluate the addition of avelumab (anti-PD-L1) to chemoradiotherapy for locally advanced squamous cell carcinoma of the head and neck, but the primary objective of prolonging progression-free survival was not met. The most common grade 3 or worse treatment-related adverse events were neutropenia, mucosal inflammation, dysphagia, and anemia.
Article
Nutrition & Dietetics
Yu-Ching Lin, Hang Huong Ling, Pei-Hung Chang, Yi-Ping Pan, Cheng-Hsu Wang, Wen-Chi Chou, Fang-Ping Chen, Kun-Yun Yeh
Summary: This study evaluated the difference in treatment-interval total body composition changes between oral cavity cancer patients with adjuvant CCRT and non-oral cavity cancer patients with primary CCRT. The study found that body composition parameters were progressively lost during CCRT in both subgroups, with different factors independently correlated with the interval changes of each body composition parameter for both groups.
Article
Medicine, General & Internal
Rui-Xue Huo, Ying-Ying Jin, Yong-Xue Zhuo, Xiao-Tong Ji, Yu Cui, Xiao-Jing Wu, Yi-Jia Wang, Long Zhang, Wen-Hua Zhang, Yu-Mei Cai, Cheng-Cheng Zheng, Rui-Xue Cui, Qian-Ye Wang, Zhen Sun, Feng-Wei Wang
Summary: The study evaluated the efficacy and safety of gemcitabine and nedaplatin as concurrent chemoradiotherapy regimens in treating HNSCC in 24 patients, showing good response rates with predictable tolerability, despite high toxicities.
WORLD JOURNAL OF CLINICAL CASES
(2022)
Article
Oncology
Nuttapong Ngamphaiboon, Arthit Chairoungdua, Thanate Dajsakdipon, Chuleeporn Jiarpinitnun
Summary: Chemoradiotherapy (CRT) is the standard treatment for locally advanced head and neck squamous cell carcinoma (LA-HNSCC) and has shown improvements in locoregional control and overall survival. Cisplatin is recommended for patients undergoing CRT, while cetuximab-radiotherapy is an alternative for those who cannot tolerate cisplatin. Although immune checkpoint inhibitors (ICIs) have shown promise in recurrent or metastatic HNSCC, their combination with radiotherapy or chemoradiotherapy in LA-HNSCC has not shown significant survival improvements. Advances in radiotherapy techniques have improved treatment outcomes for LA-HNSCC, but there is still a need for novel radiosensitizing agents. This review discusses the mechanism of radiotherapy, emerging radiosensitizing agents, and the future direction of systemic therapy in combination with radiotherapy for LA-HNSCC.
Article
Oncology
Xia Li, Qigen Fang, Wei Du, Xu Zhang, Liyuan Dai, Yongming Qiao
Summary: The addition of sintilimab to induction chemotherapy in locally advanced head and neck squamous cell carcinoma patients resulted in a significantly higher objective response rate and longer progression-free survival compared to chemotherapy alone. However, there was no significant difference in overall survival between the two groups. The incidence of grade 3 or higher acute toxicity was similar in both groups.
Article
Oncology
Meng-Che Hsieh, Chih-Chun Wang, Chuan-Chien Yang, Ching-Feng Lien, Chien-Chung Wang, Yu-Chen Shih, Shyh-An Yeh, Tzer-Zen Hwang
Summary: The primary tumor location has a significant impact on survival in patients with locally advanced head and neck squamous cell carcinoma treated with induction chemotherapy. Patients with oral cavity cancer had inferior overall survival in the induction chemotherapy group compared to the concurrent chemoradiotherapy group, while patients with non-oral cavity cancer had superior overall survival in the induction chemotherapy group.
Article
Oncology
Akira Ohkoshi, Ryo Ishii, Shun Wakamori, Yuki Nakayama, Takuya Yoshida, Kenjiro Higashi, Ayako Nakanome, Takenori Ogawa, Yukio Katori
Summary: This study demonstrates that mild renal dysfunction and selenium deficiency have negative impacts on the achievement of full-dose cisplatin in HNSCC patients undergoing CCRT, suggesting these factors as potential therapeutic targets.
Article
Oncology
Yun-Gyoo Lee, Eun Joo Kang, Bhumsuk Keam, Jin-Hyuk Choi, Jin-Soo Kim, Keon Uk Park, Kyoung Eun Lee, Keun-Wook Lee, Min Kyoung Kim, Hee Kyung Ahn, Seong Hoon Shin, Hye Ryun Kim, Sung-Bae Kim, Hyo Jung Kim, Hwan Jung Yun
Summary: Although women account for 30% of head and neck cancer cases, they have been underrepresented in clinical trials. This study aimed to compare treatment modalities and outcomes between male and female patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC). The results showed no significant differences in treatment strategies and overall survival between the sexes, suggesting no apparent sex-based disparity in the treatment and outcomes of LA-HNSCC.
Article
Nutrition & Dietetics
Takae Tsujimoto, Masafumi Wasa, Hidenori Inohara, Toshinori Ito
Summary: L-glutamine does not influence the survival of patients with locally advanced head and neck cancer receiving chemoradiotherapy.
Article
Medicine, General & Internal
Najiba Chargi, Inge Wegner, Navid Markazi, Ernst Smid, Pim de Jong, Lot Devriese, Remco de Bree
Summary: Low skeletal muscle mass is associated with toxicities and decreased survival in head and neck cancer patients. Chemoradiotherapy may exacerbate the loss of skeletal muscle mass. A high body mass index (BMI) before treatment is a key predictor of skeletal muscle mass loss. While changes in skeletal muscle mass were not prognostic for survival, low skeletal muscle mass at diagnosis and an HPV-positive oropharyngeal tumor were prognostic factors for overall survival.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Oncology
Robert L. Ferris, Kevin Harrington, Jonathan D. Schoenfeld, Makoto Tahara, Christina Esdar, Satu Salmio, Andreas Schroeder, Jean Bourhis
Summary: Standard of care for patients with locally advanced squamous cell carcinoma of the head and neck is surgery followed by chemoradiotherapy or definitive chemoradiotherapy. However, many patients experience disease recurrence or metastasis within 2 years, indicating a need for novel treatment options. Overexpression of inhibitor of apoptosis proteins (IAPs) has been identified as a key factor in treatment resistance and poor outcomes. Xevinapant, a potent IAP inhibitor, has shown promising results in combination with chemoradiotherapy in a phase 2 trial. This article explores the current treatment landscape and highlights the potential of targeting IAPs for improved outcomes.
CANCER TREATMENT REVIEWS
(2023)
Article
Oncology
Ahmed I. Ghanem, Neil M. Woody, Mathew A. Schymick, Nikhil P. Joshi, Jessica L. Geiger, Chiaojung Jillian Tsai, Neal E. Dunlap, Howard Y. Liu, Brian B. Burkey, Eric D. Lamarre, Jamie A. Ku, Joseph Scharpf, Jimmy J. Caudell, Sandro V. Porceddu, Nancy Y. Lee, David J. Adelstein, Shlomo A. Koyfman, Farzan Siddiqui
Summary: This study investigated the influence of treatment package time (TPT) on adjuvant radiotherapy with concurrent chemotherapy (CRT) in high-risk oral cavity squamous cell carcinoma (OCSCC). The results showed that patients with a TPT greater than 90 days had worse overall survival (OS), highlighting the importance of optimizing perioperative care and baseline conditions for favorable outcomes.
Article
Oncology
Bill H. H. Diplas, Armin Shahrokni, Andrew Warner, Puneeth Iyengar, Jonathan T. T. Yang, Daniel R. R. Gomez, David A. A. Palma, Patricia Mae G. Santos, C. Jillian Tsai
Summary: For patients with oligometastatic cancer, radiotherapy offers a promising option for symptom relief and disease control. This review focuses on the challenges and considerations for using radiotherapy in older adults with oligometastatic disease, emphasizing the importance of geriatric assessments in clinical decision-making. The review also discusses existing trial data, including analysis of adverse events and survival estimates among older adults in the SABR-COMET trial, and suggests the need for focused clinical trials in older adult cohorts.
SEMINARS IN RADIATION ONCOLOGY
(2022)
Article
Endocrinology & Metabolism
Nancy Y. Lee, Nadeem Riaz, Vanessa Wu, Thomas Brinkman, Chiaojung J. Tsai, Wanquing Zhi, James Fetten, Alan Ho, Richard J. Wong, Ronald Ghossein, Michael Tuttle, James Fagin, David G. Pfister, Eric Sherman
Summary: This pilot study evaluated the effectiveness of tremelimumab plus durvalumab with stereotactic body radiotherapy (SBRT) in improving overall survival (OS) in patients with metastatic anaplastic thyroid cancer (ATC). The results showed that this combination therapy did not improve OS in ATC patients. Further research is needed to explore novel immunotherapy combinations with or without radiotherapy for the treatment of ATC.
Editorial Material
Oncology
Robert C. Miller, C. Jillian Tsai
ADVANCES IN RADIATION ONCOLOGY
(2022)
Article
Oncology
Nancy Anabaraonye, Chiaojung Jillian Tsai, Hina Saeed, Fumiko Chino, Ekaete Ekpo, Sudeep Ahuja, Oscar Garcia, Robert C. Miller
Summary: During the early months of the COVID-19 pandemic, there was a decrease in the participation of nonsenior female researchers in article publishing, particularly in scientific manuscripts.
ADVANCES IN RADIATION ONCOLOGY
(2022)
Article
Oncology
Adam J. Schoenfeld, Hira A. Rizvi, Danish Memon, Narek Shaverdian, Matthew J. Bott, Jennifer L. Sauter, C. Jillian Tsai, Jayon Lihm, David Hoyos, Andrew J. Plodkowski, Rocio Perez-Johnston, Peter Sawan, Jacklynn Egger, Benjamin D. Greenbaum, Andreas Rimner, Gregory J. Riely, Charles M. Rudin, Valerie W. Rusch, Daniel R. Gomez, Matthew D. Hellmann
Summary: This study retrospectively analyzed acquired resistance to PD-(L)1 blockade and found that oligoAR is a common and distinct pattern associated with improved post-progression survival, which can be effectively managed with local therapies.
CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Jung Julie Kang, Yao Yu, Linda Chen, Kaveh Zakeri, Daphna Yael Gelblum, Sean Matthew McBride, Nadeem Riaz, C. Jillian Tsai, Anuja Kriplani, Tony K. W. Hung, James V. Fetten, Lara A. Dunn, Alan L. Ho, Jay O. Boyle, Ian S. Ganly, Bhuvanesh Singh, Eric J. Sherman, David G. Pfister, Richard J. Wong, Nancy Y. Lee
Summary: Oropharyngeal cancer (OPC) is the most common cancer caused by human papillomavirus (HPV) infection in the United States. Identifying the optimal deintensification strategy for HPV-positive OPC has been a key focus for academic head-and-neck surgery, radiation oncology, and medical oncology. The first generation of randomized chemotherapy deintensification trials did not change the standard of care, leading to concerns about de-escalation feasibility. National database studies show that a significant number of patients receive nonstandard de-escalated treatments. Synthesizing multidisciplinary deintensification data and treatment standards is important to reinforce best practices and improve patient outcomes.
CA-A CANCER JOURNAL FOR CLINICIANS
(2023)
Article
Otorhinolaryngology
Annu Singh, Sarin Kitpanit, Brian Neal, Ellen Yorke, Charlie White, SaeHee K. K. Yom, Joseph D. D. Randazzo, Richard J. J. Wong, Joseph M. M. Huryn, Chiaojung Jillian Tsai, Kaveh Zakeri, Nancy Y. Y. Lee, Cherry L. L. Estilo
Summary: This study reported the prevalence and clinical characteristics of osteoradionecrosis (ORN) in patients with oral and oropharyngeal cancer (OOPC) treated with proton radiation therapy (PRT). The results showed that the prevalence of ORN following PRT was 10.6%, indicating that ORN remains a clinical challenge even in the era of highly conformal PRT.
JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY
(2023)
Article
Medicine, General & Internal
Anna Lee, Robbie Woods, Amgad Mahfouz, Sarin Kitpanit, Olivia Cartano, Nader Mohamed, Irini Youssef, Kathryn Marqueen, Kevin Sine, Dennis Mah, Brian Neal, Kaveh Zakeri, Jung J. Kang, Nadeem Riaz, Yao Yu, Sean M. McBride, Linda D. Chen, C. Jillian Tsai, Daphna Y. Gelblum, Robert H. Press, Loren S. Michel, Eric J. Sherman, David Pfister, Lara A. Dunn, Alan L. Ho, James Fetten, Richard J. Wong, Jay O. Boyle, Bhuvanesh Singh, Jennifer R. Cracchiolo, Ian Ganly, Marc A. Cohen, Nancy Y. Lee
Summary: This retrospective cohort study evaluated the outcomes and toxic effects of proton therapy reirradiation (PT-ReRT) in patients with head and neck squamous cell carcinoma. The study found that PT-ReRT can improve survival rates, but patients are still at risk of early and late complications.
Article
Radiology, Nuclear Medicine & Medical Imaging
Eric Aliotta, Yu-Chi Hu, Peng Zhang, Phillip Lichtenwalner, Amanda Caringi, Natasha Allgood, C. Jillian Tsai, Kaveh Zakeri, Nancy Lee, Pengpeng Zhang, Laura Cervino, Michalis Aristophanous
Summary: This study developed an automated system to track anatomical changes during head and neck radiotherapy through longitudinal MRI scans. The results showed that this system can help identify rapidly responding patients as early as one week into treatment.
JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS
(2023)
Article
Oncology
Yao Yu, Heiko Schoder, Kaveh Zakeri, Linda Chen, Jung Julie Kang, Sean Matthew McBride, C. Jillian Tsai, Daphna Y. Gelblum, Jay O. Boyle, Jennifer R. Cracchiolo, Marc A. Cohen, Bhuvanesh Singh, Ian Ganly, Snehal G. Patel, Loren S. Michel, Lara Dunn, Eric J. Sherman, David G. Pfister, Richard J. Wong, Nadeem Riaz, Nancy Y. Lee
Summary: This study evaluates the impact of post-operative PET/CT on the detection of early recurrence and treatment outcomes in OSCC. The results show that patients planned with post-operative PET/CT are more likely to be diagnosed with early recurrence compared to those planned with CT only. Among patients with intermediate risk features, post-operative PET/CT is associated with improved disease-free survival.
Article
Oncology
James B. Yu, Adam P. Dicker, Nataniel H. Lester-Coll, C. Jillian Tsai, Matthew Zawalich
Summary: Radiation oncology, a technologically intensive discipline, is vulnerable to cyberattacks due to its reliance on multiple and diverse computer systems. It is crucial for radiation oncologists and their teams to minimize cybersecurity threats to their practices in order to avoid significant losses in time, energy, and money resulting from cyberattacks.
PRACTICAL RADIATION ONCOLOGY
(2023)
Editorial Material
Oncology
Robert C. Miller, C. Jillian Tsai
ADVANCES IN RADIATION ONCOLOGY
(2023)
Article
Otorhinolaryngology
James Han, Kaveh Zakeri, Gabriel Raab, Jennifer Hesse, Achraf Shamseddine, Linda Chen, Yao Yu, Jung Julie Kang, Sean M. M. McBride, Nadeem Riaz, C. Jillian Tsai, Daphna Gelblum, Eric J. J. Sherman, Richard J. J. Wong, Loren Michel, Nancy Y. Y. Lee
Summary: This study reports the outcomes of cisplatin-ineligible HNSCC patients treated with definitive chemoradiation using carboplatin and paclitaxel. The results show that chemoradiation with carboplatin and paclitaxel is an effective treatment option for controlling locoregional recurrences and distant metastases, and improving progression-free survival and overall survival in these patients.
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
(2023)
Article
Oncology
Michael Yan, Fadwa Abdel-Rahman, Laura Dawson, Philip Wong, Rebecca K. S. Wong, C. Jillian Tsai
Summary: The paradigm of oligometastatic disease presents unique opportunities and challenges in clinical trial design and implementation. This paper outlines the key challenges and suggests potential strategies to address them, emphasizing the importance of a comprehensive, patient-centric approach and the integration of multidisciplinary teams. The aim is to encourage the design of well-structured clinical trials to enhance patient outcomes.
SEMINARS IN RADIATION ONCOLOGY
(2023)